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Background: It remains unknown to what extent consensus molecular subtype (CMS) groups and immune-stromal infiltration
patterns improve our ability to predict outcomes over tumor–node–metastasis (TNM) staging and microsatellite instability (MSI)
status in early-stage colorectal cancer (CRC).
Patients and methods: We carried out a comprehensive retrospective biomarker analysis of prognostic markers in adjuvant
chemotherapy-untreated (N¼ 1656) and treated (N¼ 980), stage II (N¼ 1799) and III (N¼ 837) CRCs. We defined CMS scores
and estimated CD8þ cytotoxic lymphocytes (CytoLym) and cancer-associated fibroblasts (CAF) infiltration scores from bulk
tumor tissue transcriptomes (CMSclassifier and MCPcounter R packages); constructed a stratified multivariable Cox model for
disease-free survival (DFS); and calculated the relative proportion of explained variation by each marker (clinicopathological
[ClinPath], genomics [Gen: MSI, BRAF and KRASmutations], CMS scores [CMS] and microenvironment cells [MicroCells:
CytoLymþCAF]).
Results: In multivariable models, only ClinPath and MicroCells remained significant prognostic factors, with both CytoLym and
CAF infiltration scores improving survival prediction beyond other markers. The explained variation for DFS models of ClinPath,
MicroCells, Gen markers and CMS4 scores was 77%, 14%, 5.3% and 3.7%, respectively, in stage II; and 55.9%, 35.1%, 4.1% and
0.9%, respectively, in stage III. Patients whose tumors were CytoLym high/CAF low had better DFS than other strata [HR¼0.71
(0.6–0.9); P¼ 0.004]. Microsatellite stable tumors had the strongest signal for improved outcomes with CytoLym high scores
(interaction P¼ 0.04) and the poor prognosis linked to high CAF scores was limited to stage III disease (interaction P¼ 0.04).
Conclusions: Our results confirm that tumor microenvironment infiltration patterns represent potent determinants of the risk
for distant dissemination in early-stage CRC. Multivariable models suggest that the prognostic value of MSI and CMS groups is
largely explained by CytoLym and CAF infiltration patterns.
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Introduction
Management of locoregional colorectal cancer (CRC) is still
largely dictated by tumor–node–metastasis (TNM) status at diag-
nosis, despite the multitude of prognostic biomarker research
over the recent years. Depth of tumor wall invasion (pT1pT4)
and lymph node (LN) involvement (pN0pN2) are strongly
associated with 5-year disease-free survival (DFS), which ranges
from 30% to 90% [1, 2]. The decision to offer adjuvant chemo-
therapy, particularly in stage II relies on clinicopathological fea-
tures such as bowel obstruction or perforation at presentation,
number of LNs examined, lymphovascular or perineural invasion
and tumor grade [3]. The only molecular marker with clinical
utility in early-stage CRC is microsatellite instability (MSI),
which is universally recommended for diagnosis of Lynch
Syndrome, but also defines a stage II population (irrespective of
germline or sporadic background) with significantly improved
when treated with surgery alone [4]. There are no validated mo-
lecular markers to help identify patient populations with
increased benefit from adjuvant chemotherapy in locoregional
CRC.
Previously, we have estimated the value of clinicopathological
features, MSI and additional molecular markers, namely
BRAFV600E and KRAS exon 2 mutations, in prognostic models of
stage II/III (early-stage) CRC [4]. We found that incorporation
of MSI and driver gene mutation status to overall survival models
with TNM staging does improve the prognostic discriminatory
power, but only modestly increases prediction accuracy in multi-
variable models that include detailed clinicopathological annota-
tion, particularly in chemotherapy-treated patients. Importantly,
there was only one genomically defined subgroup of CRC with
consistently higher risk of death across multiple cohorts, namely
patients whose tumors were microsatellite stable (MSS) and
BRAFV600E mutated, which corresponded to only 6% of the stage
II/III population. Discovery of additional clinically relevant sub-
groups with potentially targetable pathway dependencies and/or
cancer microenvironment features has the potential to guide ad-
juvant treatment strategies in broader patient populations.
Tumor microenvironment markers have demonstrated inde-
pendent prognostic value in stage II/III CRC, with a high density
of CD8þ cytotoxic T lymphocyte (CytoLym) infiltration being
consistently associated with prolonged survival [5–8]. Indeed, an
immunohistochemistry-based scoring system has been developed
(termed Immunoscore
VR
) to quantify cytotoxic and memory T
cells in the tumor center/invasive margin, which proved to be a
strong prognostic index in early-stage CRC [8]. Several authors
have suggested that the dense CytoLym infiltrate could explain
the better prognosis of tumors displaying MSI, compared with
MSS CRC [9, 10]. In addition, a subset of MSS tumors harbors
prominent expression of immune cytotoxic markers (up to 30%
of the stage II/III population), and multivariable models revealed
that Immunoscore
VR
was superior to MSI status in predicting
disease-specific recurrence and patient survival [10].
Furthermore, gene expression signatures that reflect epithelial-
mesenchymal transition and tumor infiltration with cancer-
associated fibroblasts (CAFs) also constitute independent prog-
nostic indicators in early stages, with dismal outcomes for
patients with an invasive stromal-rich microenvironment [11,
12]. These markers are not as thoroughly validated as
Immunoscore(R), but they are reflected in the transcriptomic-
based consensus molecular subtypes (CMS) of CRC, which have
also been linked to patient outcome in early-stage CRC. High
CAFs content (CMS4 Mesenchymal) and CytoLym infiltration
(CMS1 MSI Immune) are important features of the tumor
microenvironment in early-stage CRC, with poor and good prog-
nosis, respectively. The dismal DFS rates for CMS4 tumors is in-
dependent of clinicopathological markers, KRAS or BRAFV600E
mutations and MSI status [13, 14]. Interestingly, CMS4 tumors
have high expression of genes specific for both CAFs and
CytoLym, counterbalanced by immunosuppressive cells, such as
Treg cells, myeloid-derived suppressor cells, monocytic derived
cells and TH17 cells [15], previously linked to chemotherapy re-
sistance [16, 17].
Given the known interactions between MSI, immune-stromal
markers and mesenchymal activation states, only an unbiased
multivariable prognostic model that incorporates TNM staging,
genomic markers, transcriptomic subtypes and microenviron-
ment features can identify the most critical drivers of disease re-
currence in CRC. It is unknown to what extent the combined
analysis of immune and stromal infiltration patterns improves
prediction of DFS over traditional clinicopathological/molecular
markers in stage II/III CRC and whether the potential prognostic
effect of microenvironment cells is modulated by adjuvant che-
motherapies. Here we describe the results of a comprehensive
retrospective biomarker analysis of prognostic markers in
chemotherapy-untreated and treated stage II/III CRCs from a
large aggregated cohort of clinical studies with molecular data.
Our hypothesis was that microenvironment features constitute
stronger determinants of disease recurrence in early-stage CRC
than genomic or transcriptomic subtypes. We aimed to perform
a holistic assessment of the prognostic value of well-known in-
trinsic biological features of CRC.
Methods—patient population and
molecular data
To perform this analysis, we aggregated data from multiple public
cohorts and collaborated with different academic groups to have
access to private data from prospective series and one clinical trial
(Alliance CALGB9581). This project was approved by the Vall
d’Hebron Institute of Oncology Ethics Committee. Patients
signed informed consent for exploratory biomarker research on
samples prospectively collected in accordance with the guidelines
of Institutional Review Boards from each organization/clinical
trial. Table 1 summarizes the final study population that included
2636 patients diagnosed with stage II/III CRC, untreated
(N¼ 1656) or treated (N¼ 980) with adjuvant chemotherapy,
with clinicopathological and molecular annotation for variables
of interest. Transcriptomic data were normalized following
standard bioinformatics procedures for CMSclassifier and
MCPcounter application independently in each cohort (see sup-
plementary Table S1, available at Annals of Oncology online for
details on gene expression platform and tissue source). We
obtained CMS1, CMS2, CMS3 and CMS4 Random Forest poster-
ior probabilities as a continuous value (each ranging from 0–1)
and final CMS labels using CMSclassifer R-package [13].
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Likewise, the abundance of immune- and nonimmune-stromal
cell populations was estimated from gene expression data using
MCPcounter R-package [18]. Given the fact that MCPcounter
scores are affected by gene expression platform and tissue source,
microenvironment cell infiltration scores were scaled (from 0 to
1) first within three subgroups [Affymetrix in fresh frozen
samples; Agilent in fresh frozen samples; and Almac-Affymetrix
in formalin-fixed paraffin-embedded (FFPE) samples] and then
rescaled after data aggregation to facilitate cross-study compari-
sons. Multiple imputation of random missing values was carried
out via the mice R package in the aggregated cohort (supplemen-
tary Table S2, available at Annals of Oncology online).
Table 1. Patient’s and tumor characteristics
All (N5 2636) No adjuvant
chemotherapy
(N5 1656)
Adjuvant
chemotherapy
(N5 980)
Dataset public Variable n % n % n %
E-MTAB-864 144 48.37% 144 49.15% 0 47.04%
GSE14333 183 99 84
GSE17536 109 55 54
GSE24550 76 57 19
GSE31595 37 26 11
GSE33113 87 87 0
GSE37892 128 71 57
GSE38832 72 34 38
GSE39582 439 241 198
Dataset private CRCSC 589 51.63% 110 50.85% 479 52.96%
Oslo 281 241 40
CALGB9581 393 393 0
Colonomics 98 98 0
Age Median (minmax) 69 (22 97) 70 (24–97) 65 (22–97)
Sex Male 1382 52.43% 867 52.36% 515 52.55%
Female 1254 47.57% 789 47.64% 465 47.45%
Stage T1-2N0 5 0.19% 5 0.30% 0 0%
T3N0 1606 60.93% 1322 79.83% 284 28.98%
T4N0 188 7.13% 140 8.45% 48 4.90%
T1-2N1 41 1.56% 13 0.79% 28 2.86%
T3N1 461 17.49% 117 7.07% 344 35.10%
T4N1 54 2.05% 13 0.79% 41 4.18%
T1-2N2 6 0.23% 2 0.12% 4 0.41%
T3N2 232 8.80% 37 2.23% 195 19.90%
T4N2 43 1.63% 7 0.42% 36 3.67%
Primary site Right colon 1292 49.01% 860 51.94% 432 44.08%
Left colon 1177 44.65% 683 41.24% 494 50.41%
Rectum 167 6.34% 113 6.82% 54 5.51%
Microsatellite status Stable (MSS) 2184 82.85% 1343 81.10% 841 85.82%
Instable (MSI) 452 17.15% 313 18.90% 139 14.18%
BRAFV600E status Wt 2306 87.48% 1414 85.39% 892 91.02%
Mut 330 12.52% 242 14.61% 88 8.98%
KRAS codons 12/13 status Wt 1684 63.88% 1057 63.83% 627 63.98%
Mut 952 36.12% 599 36.17% 353 36.02%
CMS label CMS1 507 19.23% 339 20.47% 168 17.14%
CMS2 1062 40.29% 673 40.64% 389 39.69%
CMS3 337 12.78% 218 13.16% 119 12.14%
CMS4 551 20.90% 334 20.17% 217 22.14%
Mixed 179 6.79% 92 5.56% 87 8.88%
CMS4 score Median (IQR) 0.10 (0.02–0.38) 0.10 (0.02–0.35) 0.11 (0.02–0.43)
Cytotoxic lymphocyte (CytoLym)
infiltration score
Median (IQR) 0.43 (0.38–0.49) 0.43 (0.37–0.5) 0.43 (0.38–0.49)
Cancer-associated fibroblast (CAF)
infiltration score
Median (IQR) 0.59 (0.49–0.67) 0.59 (0.48–0.67) 0.59 (0.51–0.67)
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Methods—multivariable survival modeling
Our primary end point was DFS, measured from time of cancer
diagnosis until disease relapse or death from any cause. Survival
was censored at 72 months based on median follow-up of patients
alive. The covariates considered for inclusion in the prognostic
models were as follows:
(i) Clinicopathological features (ClinPath): AJCC version 7
pathological tumor stage (pT-stage; pT1, pT2, pT3 and
pT4) and pathological nodal stage (pN-stage: pN0, pN1
and pN2), age (continuous), sex (male versus female), pri-
mary tumor location [right (caecum to transverse colon)
versus left (splenic flexure to sigmoid) or rectum].
(ii) Genomic markers (Gen): MSI status (MSI high versus
MSS or MSI low), mutations in KRAS codons 12/13 or
BRAFV600E (versus wild-type).
(iii) Transcriptomic markers (CMS groups): CMS labels either
as categorical variables (CMS1, CMS2, CMS3 or CMS4) or
as independent continuous scores (CMS1 score, CMS2
score, CMS3 score, CMS4 score) from CMSclassifier R
package [13].
(iv) Microenvironment infiltration markers (MicroCells):
MCPcounter R package scores predict the abundance of 10
cell populations from transcriptomic profiles (CD3þ T cells,
CD8þ T cells [CytoLym], CTLs [cytotoxic lymphocytes],
NK [Natural Killer] cells, B lymphocytes, monocytic lineage
cells, myeloid dendritic cells, neutrophils, endothelial cells
and CAFs) [18] as a continuous variable.
Study methodology is summarized in supplementary Figure
S1, available at Annals of Oncology online. First, following data ag-
gregation and imputation, we assessed proportional hazards as-
sumption using survival R package. Sex did not hold the
assumption of proportional hazards (P< 0.05) and was included
in the survival models as a stratification variable, together with
gene expression profiling subgroups as defined above
(Affymetrix fresh-frozen; Agilent fresh-frozen; Affymetrix-Almac
FFPE) and adjuvant chemotherapy status. In order to select varia-
bles within the CMS and MicroCells categories with the highest
prognostic impact on DFS estimation, we carried out forward
and backward stepwise regression using the Bayesian information
criterion. Then, multivariable Cox proportional hazards models
were formulated using all factors that demonstrated statistical
significance for DFS in univariate models (with P< 0.1 according
to log-rank test). We investigated significant interactions among
genomic, transcriptomic, microenvironment infiltration markers
and clinicopathological features with impact on patient out-
comes (P< 0.05 according to ANOVA test). Next, the following
multivariable models were compared: (i) ClinPath þGen; (ii)
ClinPath þGen þCMS; (iii) ClinPath þGen þMicroCells; and
(iv) ClinPath þGen þCMS þMicroCells. We then calculated,
using multiple permutations, the relative proportion of explained
variation in DFS that was accounted for by the different
categories of predictor covariates using survMisc R package [19].
For illustration purposes, continuous scores (CMS and micro-
environment cell infiltration) were dichotomized based on the
maximization of the log-rank statistic to generate KaplanMeier
DFS curves using survminer R package. All analyses were carried
out using R statistical software version 3.2.5 [20].
Results
Demographics, tumor-related characteristics and molecular
markers of the numerous cohorts of patients with stage II or stage
III CRC included in survival models are described in Table 1.
Patients were recruited in the different studies between 1990 and
2005. Clinicopathological features of our population are in line
with other prospective biomarker series (non-clinical trial
cohorts), including a relatively elderly population, with stage II
representing 85% and 35% of the cases in the untreated and
chemotherapy-treated cohorts, respectively. Information on type
of adjuvant chemotherapy is missing in most public cohorts, but
given the standards of treatment at time of study recruitment, we
estimate that<10% of the combined publicprivate treated pop-
ulations received oxaliplatin in addition to 5-fluorouracil. The
prevalence of molecular markers also mirrors published litera-
ture, with 17% MSI tumors, 36% KRAS codons 12/13 mutated,
13% BRAFV600E mutated and 21% CMS4 tumors.
In the variable selection process, CMS4 as a continuous score
was a better predictor of DFS than CMS 1/2/3 scores or CMS 1/2/
3/4 labels. Also, from 10 MicroCells populations, CytoLym and
CAFs infiltration scores were the strongest predictors of DFS. We
found no significant inter-study heterogeneity when assessing
CytoLym and CAFs scores as dichotomous variables in DFS mod-
els (supplementary Figure S2, available at Annals of Oncology on-
line). On average, CytoLym infiltration scores were highest in
CMS1 samples, while CAF scores were highest in CMS4 samples
(supplementary Figure S3, available at Annals of Oncology on-
line). Indeed, 66% of CMS1 tumors fall in the CytoLym high cat-
egories, 65% of CMS2 and CMS3 samples are classified as
CytoLym low/CAF low and 49% of CMS4 samples are CytoLym
low/CAF high (supplementary Figure S3, available at Annals of
Oncology online). We also found high association between
CytoLym infiltration scores and microsatellite status, with 68%
of MSI tumors in the CytoLym high categories (supplementary
Figure S4, available at Annals of Oncology online).
Clinicopathological and genomic markers, together with con-
tinuous CMS4 scores and CytoLym/CAF infiltration scores, were
assessed in univariate and multivariable models detailed in
Table 2. Importantly, only age, pT stage, pN stage, primary tumor
location and immune-stromal infiltration scores were independ-
ent prognostic factors in multivariable models. Patients with
right-sided tumors had better DFS outcomes than left-sided pri-
maries, both in stage II and III CRC. MSI status and CMS4 scores
did not significantly improve prognosis prediction over ClinPath
features when CytoLym and CAFs infiltration scores were consid-
ered. Analysis of deviance showed that the addition of CytoLym
and CAF infiltration scores to ClinPathþ Genþ/ CMS models
provides significant prognostic information (ANOVA P< 0.05),
as detailed in supplementary Table S3, available at Annals of
Oncology online. We found a significant interaction between MSI
status and CytoLym scores on DFS models (interaction
P¼ 0.04), with MSS tumors having the strongest signal for
improved outcomes when displaying CytoLym high infiltration
scores.
Figure 1 illustrates adjusted KaplanMeier DFS curves by
CytoLym and CAF infiltration scores in chemotherapy-untreated
and treated cohorts, as well as stage II and III CRC populations.
Overall, CytoLym high/CAF low population represented 16% of
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samples, compared with 18% with CytoLym high/CAF high, 22%
with CytoLym low/CAF high and 44% harboring CytoLym low/
CAF low scores. Patients whose tumors were CytoLym high/CAF
low had better DFS than other strata [adjusted HR ¼0.71 (0.6–
0.9); P¼ 0.004]. In both untreated and treated cohorts
(Figure 1A and B), patients with CytoLym low/CAF high infiltra-
tion scores had the highest risk of disease recurrence. In the un-
treated population, patients with CytoLym high/CAF low tumors
had significantly better DFS than CytoLym low/CAF high tumors
(Figure 1A). In both untreated and stage II CRC, CytoLym infil-
tration scores were a critical determinant of prognosis, with sig-
nificant differences in DFS when comparing CytoLym high
versus CtyoLym low categories (Figure 1A and C). The same
associations were found in both chemotherapy-treated and stage
III CRC, but CAF infiltration scores helped segregate the strata
even further (Figure 1B and D). Indeed, the poor DFS outcomes
linked to high CAF infiltration scores were limited to stage III
CRC (interaction P¼ 0.04). We found no major differences in
CytoLym and CAF infiltration scores between stage III low-risk
(T13, N1) and high-risk (T4 or N2) groups (supplementary
Figure S5, available at Annals of Oncology online). However,
31.3% of high-risk stage III tumors are classified as CytoLym low/
CAF high, while 24.5% of low-risk stage III patients fall into this
category. Individual KaplanMeier DFS curves stratified by stage
plus adjuvant chemotherapy exposure can be found in supple-
mentary Figure S6, available at Annals of Oncology online.
Figure 2 illustrates the relative contribution of different factors
for prognosis prediction in early-stage CRC. Across all cohorts,
the explained variation in multivariable DFS models for clinico-
pathological features, microenvironment infiltration scores, gen-
omic markers and CMS4 scores were 83%, 11.4%, 3.7% and
1.9%, respectively. The relative contribution of clinicopathologi-
cal features in prognosis prediction was larger in stage II as
compared with stage III disease, while the impact of tumor
microenvironment features on DFS is not diminished in more
advanced stages of locoregional CRC (Figure 2C and D). In un-
treated and stage II cohorts (Figure 2A and C), in addition to
CytoLym infiltration scores, age was an important contributor to
DFS estimation, potentially associated with competing death
risks. In adjuvant chemotherapy-treated and stage III cohorts
(Figure 2B and C), CAF infiltration scores had substantial impact
on DFS estimation.
Discussion
In this study, we investigated whether intrinsic gene expression
signatures from cancer and microenvironment cells in stage II/III
CRC have significant impact on DFS models adjusted for clinico-
pathological and genomic markers. For the first time, we show
that the prognostic value of CMS groups is largely explained by
tumor microenvironment infiltration patterns. In fact, CytoLym
and CAF infiltration scores obviate the prognostic value of MSI
status and CMS4 scores in multivariable models. We found that a
high CytoLym infiltrated microenvironment is a critical deter-
minant of improved outcomes and this ‘protective’ effect is
strong across clinicopathological and genomic subgroups. Low
microenvironment cytotoxic lymphocyte counts associates with
higher chances of disease recurrence or death, particularly when
tumors have a stromal invasive phenotype infiltrated with CAFs.
Our results are in line with extensive literature built on pathology
assessments of the tumor microenvironment showing the pro-
tective role of high infiltration by CD8þ cytotoxic T cells (ap-
proximately one-third of early-stage CRC population) [8] and
the unfavorable outcome of patients whose tumors harbor high
infiltration with stromal fibroblasts (40% of early-stage CRC
Table 2. Univariate and multivariable disease-free survival Cox models (stratified by sex, gene expression profiling platform and adjuvant chemotherapy
status)
Disease-free survival Cox models (all patients) (N52 636 769 events)
Univariate analysis Multivariable analysis
HR 95% CI P value HR 95% CI P value
Age 1.01 1–1.02 <0.001 1.01 1–1.02 <0.001
pT2/pT1 versus pT3 1.07 0.65–1.75 0.8 0.86 0.52–1.43 0.56
pT4 versus pT3 1.37 1.11–1.69 0.003 1.46 1.18–1.81 <0.001
pN1 versus pN0 1.99 1.61–2.46 <0.001 2.05 1.65–2.55 <0.001
pN2 versus pN0 3.08 2.41–3.93 <0.001 3.15 2.45–4.05 <0.001
Rectum versus left 1.03 0.76–1.40 0.83 0.94 0.69–1.29 0.72
Right versus left 0.84 0.72–0.97 0.02 0.86 0.73–1.00 0.05
MSI versus MSS 0.76 0.61 –0.93 0.008 0.88 0.7–1.11 0.29
KRAS mut versus wild-type 1.04 0.9–1.21 0.55   
BRAF mut versus wild-type 0.9 0.72 1.13 0.35   
CMS4 score 1.37 1.07–1.76 0.01 0.93 0.64–1.32 0.67
CAF infiltration score 1.6 0.93–2.74 0.09 2.54 1.08–6.02 0.03
CytoLym infiltration score 0.45 0.25–0.78 0.005 0.26 0.12–0.55 <0.001
CAF, cancer-associated fibroblast; CytoLym, cytotoxic lymphocytes. P values 0.05 displayed in bold.
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population) [21]. Our data also suggest that the worse outcomes
repeatedly seen in patients whose tumors display a mesenchymal-
like phenotype may be directly linked to a prometastatic immune
evasive and stromal-rich microenvironment. In fact, the impact
of CAF infiltration scores on DFS estimation was larger in
stage III and treated populations, which may be linked to a
chemotherapy-resistance phenotype [16, 17]. Still, most CRC
tumors have a ‘microenvironment desert’ phenotype, previously
linked to epithelial CRC subtypes (CMS2 Canonical and CMS3
Metabolic) [15], known to have intermediate prognosis in early-
stage disease. Here, the prognostic effect of cancer cell-intrinsic
genomic markers may be more profound, as previously illus-
trated for KRAS mutations [22].
Although our results confirm the notion that activated im-
mune cytotoxicity represents a potent determinant of the risk of
distant dissemination, it is also known that immune and stromal
infiltration patterns can be predicted by assessing intrinsic tumor
cell epithelial expression profiles in early-stage CRC samples
[23]. Moreover, interactions between immune cells, checkpoint
expression and MSI status do have a clinically significant impact
on prognosis. The expression levels of Immunoscore-like meta-
genes confers favorable prognosis in CRC patients with MSS
tumors displaying low levels of CytoLym and immune check-
points [24]. On the other hand, the expression levels of immune
checkpoints annuls the prognostic relevance of CytoLym in high-
ly immunogenic colon tumors and predicts a poor outcome in
MSI CRC patients. These results are in line with our data showing
a stronger signal for improved outcomes with CytoLym high
scores mainly in the MSS population. To summarize, these data
suggest that microenvironment markers must be analyzed along-
side cancer cell genomic and transcriptomic markers for proper
risk stratification.
Our study has limitations related to the retrospective, non-
randomized nature of most patient cohorts included in the ana-
lysis, with missing values for some genomic markers such as
KRAS, BRAFV600E mutations and MSI status in the range of
30%50% in some cohorts. Therefore, no definite conclusions
can be obtained from our study on the role of genomic markers
for prognostication in early-stage CRC. Larger and more contem-
porary cohorts are needed to investigate whether the prognostic
effect of microenvironment cells is modulated by adjuvant che-
motherapies, particularly oxaliplatin-based. On the other hand,
our study describes the largest cohort of untreated early-stage
CRC patients with clinical, genomic and transcriptomic features,
the ideal setting for multivariable survival modeling. In addition,
prospective non-clinical trial series included in our analyses are
representative of ‘real world’ populations. Indeed, recent insights
on clinicopathological prognostic markers, such as primary
tumor location, were validated in our aggregated cohort. In a re-
cent SEER database study and a British Columbia cohort, stage II
right-sided cancers had better cause-specific survival and relapse-
free survival than the left-sided cancers, respectively [25, 26]. In
stage III disease, right-sided poorly differentiated mucinous
adenocarcinoma showed significantly better survival than left-
sided malignancies [25]. These results could be explained by the
higher prevalence of MSI in right-sided high-grade tumors. We
Figure 1. Adjusted disease-free survival (DFS) KaplanMeier curves stratified by CytoLym and CAF groups, estimated with multivariable Cox
proportional hazard model controlling for pT, pN, age, sex, primary tumor location, MSI status and CMS4 scores:chemotherapy untreated (A),
chemotherapy treated (B), stage II (C) and stage III (D) CRC cohorts.
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also found improved DFS for right-sided early-stage CRC when
compared with left-sided disease, both in stage II and III disease.
Interestingly, in a multivariable model, sidedness remained an in-
dependent prognostic factor when adjusting for MSI status. Our
findings may be partly explained by unique patient characteristics
included in population studies, such as a large proportion of eld-
erly females.
To conclude, our data reinforce the idea that tumor micro-
environment features should guide biomarker-drug co-develop-
ment in the adjuvant setting. With recent advances in targeted
immunotherapeutic interventions, we may be able to successfully
boost anticancer immune cytotoxicity or inhibit immunosup-
pressive pathway dependencies that facilitate metastatic spread.
The major impact of CAF infiltration scores on DFS of stage III
and chemotherapy-treated populations deserves further valid-
ation in recent clinical trial cohorts, such as the IDEA consor-
tium. We believe that our results will encourage clinical trial
design with novel agents capable of reverting a chemotherapy-
resistance phenotype linked to a distinct tumor microenvironment.
When combined with liquid biopsies for detection of minimal re-
sidual disease [27], tumor and microenvironment biomarkers will
eventually help personalize adjuvant therapies in early-stage CRC.
Funding
This study was supported by Merck KGaA, Darmstadt, Germany
(Grant for Oncology Innovation 2015, ‘Next generation of clinic-
al trials with matched targeted therapies in colorectal cancer’).
Merck KGaA reviewed the manuscript for medical accuracy only
before journal submission. The authors are fully responsible for
the content of this manuscript, and the views and opinions
described in the publication reflect solely those of the authors.
This work was also supported by the Norwegian Cancer Society
(project numbers 6824048-2016 and 182759-2016) and the
Research Council of Norway (project number 250993). VM
received fund from the Instituto de Salud Carlos III, co-funded
by FEDER funds—a way to build Europe—grant PI14-00613, the
Figure 2. Relative proportion of explained variation in disease-free survival (DFS) of the full multivariable model in chemotherapy untreated
(A), chemotherapy treated (B), stage II (C) and stage III (D) CRC cohorts.
Original article Annals of Oncology
1628 | Dienstmann et al. Volume 30 | Issue 10 | 2019
Agency for Management of University and Research Grants
(AGAUR) of the Catalan Government grant 2017SGR723 and
the Scientific Foundation of the Spanish Association Against
Cancer (AECC). RSW was supported by a grant from the NIH
(RO184018).
Disclosure
RD has received speaker fee from Roche, Symphogen, Ipsen,
Amgen, Sanofi, Servier, MSD and had advisory roles for Roche
and Novartis over the last 2 years. RD and JG received research
grant from Merck from 2015 to 2017. RAL received a Board of
Directors member fee from Inven2, an innovation company for
research at Oslo University Hospital and the University of Oslo.
VM has received research funds from Universal Diagnostics and
Bioiberica and had advisory role for Ferrer. All remaining authors
have declared no conflicts of interest.
References
1. Siegel R, Miller KD, Fedewa SA et al. Colorectal cancer statistics, 2017.
CA Cancer J Clin 2017; 64: 177–193.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence
and mortality patterns in Europe: estimates for 40 countries in 2012. Eur
J Cancer 2013; 49(6): 1374–1403.
3. Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adju-
vant therapy: selecting optimal treatments for individual patients. J Clin
Oncol 2015; 33(16): 1787–1796.
4. Dienstmann R, Mason MJ, Sinicrope FA et al. Prediction of overall sur-
vival in stage II and III colon cancer beyond TNM system: a retrospect-
ive, pooled biomarker study. Ann Oncol 2017; 28(5): 1023–1031.
5. Mlecnik B, Bindea G, Kirilovsky A et al. The tumor microenvironment
and Immunoscore are critical determinants of dissemination to distant
metastasis. Sci Transl Med 2016; 8(327): 327ra26.
6. Mlecnik B, Tosolini M, Kirilovsky A et al. Histopathologic-based prog-
nostic factors of colorectal cancers are associated with the state of the
local immune reaction. J Clin Oncol 2011; 29(6): 610–618.
7. Sinicrope FA, Smyrk TC, Foster NR et al. Association of tumor infiltrat-
ing lymphocytes with molecular subtype and prognosis in stage III colon
cancers from a FOLFOX-based adjuvant chemotherapy trial. J Clin
Oncol 2016; 34 (Suppl 15): 3518.
8. Page`s F, Mlecnik B, Marliot F et al. International validation of the con-
sensus Immunoscore for the classification of colon cancer: a prognostic
and accuracy study. Lancet 2018; 391(10135): 2128–2139.
9. Bauer K, Nelius N, Reuschenbach M et al. T cell responses against micro-
satellite instability-induced frameshift peptides and influence of regula-
tory T cells in colorectal cancer. Cancer Immunol Immunother 2013;
62(1): 27–37.
10. Mlecnik B, Bindea G, Angell HK et al. Integrative analyses of colorectal
cancer show immunoscore is a stronger predictor of patient survival
than microsatellite instability. Immunity 2016; 44(3): 698–711.
11. Berdiel-Acer M, Berenguer A, Sanz-Pamplona R et al. A 5-gene classifier
from the carcinoma-associated fibroblast transcriptomic profile and
clinical outcome in colorectal cancer. Oncotarget 2014; 5(15):
6437–6452.
12. Calon A, Lonardo E, Berenguer-Llergo A et al. Stromal gene expression
defines poor-prognosis subtypes in colorectal cancer. Nat Genet 2015;
47(4): 320–329.
13. Guinney J, Dienstmann R, Wang X et al. The consensus molecular sub-
types of colorectal cancer. Nat Med 2015; 21(11): 1350–1356.
14. Song N, Pogue-Geile KL, Gavin PG et al. Clinical outcome from oxalipla-
tin treatment in stage II/III colon cancer according to intrinsic subtypes:
secondary analysis of NSABP C-07/NRG Oncology Randomized Clinical
Trial. JAMA Oncol 2016; 2(9): 1162–1169.
15. Becht E, de Reynies A, Giraldo NA et al. Immune and stromal classifica-
tion of colorectal cancer is associated with molecular subtypes and rele-
vant for precision immunotherapy. Clin Cancer Res 2016; 22(16):
4057–4066.
16. Roepman P, Schlicker A, Tabernero J et al. Colorectal cancer intrinsic
subtypes predict chemotherapy benefit, deficient mismatch repair and
epithelial-to-mesenchymal transition. Int J Cancer 2014; 134(3):
552–562.
17. Straussman R, Morikawa T, Shee K et al. Tumour micro-environment
elicits innate resistance to RAF inhibitors through HGF secretion. Nature
2012; 487(7408): 500–504.
18. Becht E, Giraldo NA, Lacroix L et al. Estimating the population abun-
dance of tissue-infiltrating immune and stromal cell populations using
gene expression. Genome Biol 2016; 17(1): 218.
19. Royston P. Explained variation for survival models. Stata J 2 6(6):
83–96.
20. R Development Core Team. R: A Language and Environment for
Statistical Computing. Vienna: R Foundation for Statistical Computing
2008. http://www.r-project.org/.
21. Huijbers A, van Pelt GW, Kerr RS et al. The value of additional bevacizu-
mab in patients with high-risk stroma-high colon cancer. A study within
the QUASAR2 trial, an open-label randomized phase 3 trial. J Surg
Oncol 2018; 117(5): 1043–1048.
22. Smeby J, Sveen A, Merok MA et al. CMS-dependent prognostic impact
of KRAS and BRAFV600E mutations in primary colorectal cancer. Ann
Oncol 2018; 29(5): 1227–1234.
23. Wirapati P, Qu X, Huw L et al. Prognostic stromal and immune response
expression patterns in early-stage colorectal cancer predicted by genes in-
trinsically expressed by tumor epithelial cells. J Clin Oncol 2019;
37(Suppl); 3601.
24. Marisa L, Svrcek M, Collura A et al. The balance between cytotoxic T-cell
lymphocytes and immune checkpoint expression in the prognosis of
colon tumors. J Natl Cancer Inst 2018; 110(1): 68–77.
25. Li Y, Feng Y, Dai W et al. Prognostic effect of tumor sidedness in colorec-
tal cancer: a SEER-based analysis. Clin Colorectal Cancer 2019; 18(1):
e104–e116.
26. Kennecke HF, Yin Y, Davies JM et al. Prognostic effect of sidedness
in early stage versus advanced colon cancer. Health Sci Rep 2018; 1(8):
e54.
27. Dasari A, Grothey A, Kopetz S. Circulating tumor DNA-defined minimal
residual disease in solid tumors: opportunities to accelerate the develop-
ment of adjuvant therapies. J Clin Oncol 2018; 35: 3437–3440.
Annals of Oncology Original article
Volume 30 | Issue 10 | 2019 doi:10.1093/annonc/mdz287 | 1629
